Riskpilot← Back to searchSign inGet full accessCumedicus AB
ABActiveOrg 5568761117Köpmannagatan 36Medical specialists activities · NACE 8622Est. 20111 employees
Revenue 2024
SEK 2,5M
+129% vs 2023
EBITDA margin
55.5%
+553% vs 2023
Equity ratio
49.3%
Financial strength
Net profit 2024
SEK 1,3M
+485% vs 2023
| Revenue | SEK 2,5M | +129% |
| EBITDA | SEK 1,4M | +553% |
| Net profit | SEK 1,3M | +485% |
| Total assets | SEK 2,7M | +353% |
| Equity | SEK 1,3M | +376% |
| Employees | 1 | — |
Legal name
Cumedicus AB
Org number
5568761117
Legal form
Aktiebolag
NACE code
8622 · Medical specialists activities
Founded
13 december 2011
Share capital
SEK 50 000
Employees
1 (FTE)
VAT registered
Yes
Audit selected
No
Last report
2024-12-31
Financial year
January – December
Signatory rights
Firman tecknas av styrelsen
Company purpose
Bolaget skall bedriva verksamhet inom hälso- och sjukvård och naturvetenskaplig forskning och utveckling och därmed förenlig verksamhet, samt handel med och förvaltning av värdepapper.
Address
Köpmannagatan 36
Email
fredrikahlander@gmail.com
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
| Item | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
| Revenue | 690 | 482 | 266 | 1 111 | 2 541 |
| Staff expenses | — | — | — | — | — |
| EBITDA | 195 | −152 | −44 | 216 | 1 411 |
| Depreciation & amort. | −13 | −13 | −13 | −0 | −0 |
| EBIT | 182 | −165 | −57 | 216 | 1 411 |
| Net financials | — | — | — | 1 | 566 |
| Profit before tax | 181 | −165 | −57 | 217 | 1 577 |
| Tax | −35 | −0 | −0 | −3 | −325 |
| Net profit | 146 | −165 | −57 | 214 | 1 252 |
| Item | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
| Total assets | 483 | 272 | 139 | 597 | 2 703 |
| Equity | 289 | 123 | 66 | 280 | 1 332 |
| Long-term debt | 0 | 0 | 0 | 0 | 0 |
| Short-term debt | 194 | 149 | 73 | 317 | 971 |
| Total debt | 194 | 149 | 73 | 317 | 971 |
EBITDA margin
55.5%
This company
15.8%
Market median
+251% vs market
20202024
Equity ratio
49.3%
This company
38.2%
Market median
+29% vs market
20202024
Return on equity
94.0%
This company
18.4%
Market median
+411% vs market
20202024
Net profit margin
49.3%
This company
8.1%
Market median
+509% vs market
20202024
Asset turnover
0.94×
This company
1.12×
Market median
+16% vs market
20202024
Debt / equity
1.03×
This company
0.62×
Market median
-66% vs market
20202024
- Annual report 2024Filed via Bolagsverket / SCB · Period 2024-01-01 – 2024-12-31
- Annual report 2023Filed via Bolagsverket / SCB · Period 2023-01-01 – 2023-12-31
- Annual report 2022Filed via Bolagsverket / SCB · Period 2022-01-01 – 2022-12-31
- Annual report 2021Filed via Bolagsverket / SCB · Period 2021-01-01 – 2021-12-31
- Annual report 2020Filed via Bolagsverket / SCB · Period 2020-01-01 – 2020-12-31
No data on file.
| Name | Role | Member since |
|---|---|---|
| Current (2) | ||
| Board of Directors | 2022 | |
| Deputy Board Member | 2022 | |
No shareholder data available.
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.
No registered parent or subsidiaries
Board members of Cumedicus AB also hold positions in 0 other companies.
| Person | Role here | Other companies |
|---|---|---|
| Fredrik Lars Magnus Åhlander | Board of Directors | 0 companies |
| Sara Catharina Larsson | Deputy Board Member | 0 companies |